Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* healthy 2-10 years of age children, inclusive and for whom, after the nature of the study has been explained, the parent or legal guardian has provided written informed consent~* who are available for all visits and telephone calls scheduled for the study~* who are up-to-date with age-appropriate routine childhood vaccinations~Exclusion Criteria:~* whose parent or legal guardian is unwilling or unable to give written informed consent~* who had a previous or suspected disease caused by N. meningitidis;~* who have previously been immunized with a meningococcal vaccine or vaccine containing meningococcal antigen(s)~* who have received any investigational agents or vaccines within 90 days prior to enrollment~* who have any serious acute, chronic or progressive disease~* who have epilepsy or any progressive neurological disease or history of Guillain Barré Syndrome~* who have a history of anaphylaxis, serious vaccine reactions~* who have a known or suspected impairment/alteration of immune function, either congenital or acquired or resulting from~* who are known to have a bleeding diathesis, or any condition that may be associated with a prolonged bleeding time~* who have Down's syndrome or other known cytogenic disorders

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 10 Years
- Healthy Volunteers: t

Study Arms:
- MenACWY-CRM (1 dose) (Type: EXPERIMENTAL): 1 injection of the Novartis MenACWY-CRM (a nontoxic mutant of diptheria toxin) conjugate vaccine administered by intramuscular (IM) injection on study day 1.
- Licensed polysaccharide vaccine (Type: ACTIVE_COMPARATOR): 1 injection of a licensed meningococcal MenACWY polysaccharide-protein conjugate vaccine administered by intramuscular (IM) injection on study day 1
- MenACWY-CRM (2 doses) (Type: EXPERIMENTAL): 2 injections of the Novartis MenACWY-CRM (a nontoxic mutant of diptheria toxin) conjugate vaccine administered by intramuscular (IM) injection on study days 1 and 61.

Based on this trial design, predict the completion outcome and termination type (if applicable).